DENVER, March 24, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine” or the “Company’), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced it has received conditional approval from the Institutional Review Board (IRB) for its multi-site Phase 2b smoking cessation trial. Johns Hopkins University will serve as the lead investigational site.
Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Technology%20abstract%20by%20TU%20IS%20via%20iStock.jpg)
